HONG KONG, May 20, 2025 /PRNewswire/ — A research team led by Hong Kong Baptist University (HKBU) has developed a novel catalytic membrane that can substantially boost the efficiency of cleaning wastewater using a modified advanced oxidation process (AOP). The invention contributes to the effort of tackling environmental pollution problems by offering a safer, more cost-effective, and environmentally friendly solution for wastewater treatment.

The research findings have been published in the international academic journal Advanced Functional Materials.

Novel technology targeting phenolic pollutants

Water pollution is a pressing environmental issue. Phenolic compounds are a major group of pollutants that pose a significant threat to the world’s potable water supply. They are widely present in industrial effluents, agricultural runoff and municipal wastewater. They can persist in the environment for long periods, accumulate in living organisms and pose significant risks to human health and water quality. Traditional methods for removing phenolic pollutants often require hazardous chemicals or energy-intensive processes.

AOPs have been increasingly recognised and developed over the past few decades to remove pollutants from water. They are a set of chemical treatment methods which activate oxidants into reactive oxygen species (ROS) that can be used to break down pollutants in wastewater. Among these ROS, singlet oxygen (1O2) is particularly effective in targeting phenolic compounds.

More efficient in generating ROS

However, existing methods to generate ROS usually require strong oxidants and energy inputs as catalysts, which can be costly and environmentally unfriendly. Moreover, traditional AOP systems face two significant challenges: the inefficient transfer of molecular oxygen (O2) in water due to its low solubility, and the difficulty in getting pollutants to interact with the catalyst surface due to the surrounding water film as a barrier.

In response to these issues, a research team led by Professor Zhao Jun, Associate Professor of the Department of Biology at HKBU, has developed a novel catalytic membrane named “NGCF-OV”. It is made from a composite material that combines two advanced materials, N-doped reduced graphene oxide and cobalt ferrite. This membrane offers a promising solution for AOP and addresses the challenge of efficiently activating molecular oxygen to become 1O2.

Proven efficacy in degrading bisphenol A

The NGCF-OV membrane contains unique sites (asymmetric Co-OV-Fe sites) that can adjust the bond length of O2, i.e., the distance between the centres of the two oxygen atoms that are bonded together, and thus facilitate faster and more efficient electron transfer. As a result, 1O2 can be produced without the need for other catalytic agents and external energy inputs. Additionally, the membrane also features graphitic nitrogen sites that trap pollutants close to the membrane’s surface. The distance between the pollutants and the 1O2 molecules generated is therefore significantly reduced, overcoming the water film barrier issue with reaction efficiency greatly improved. 

The NGCF-OV membrane demonstrated superior efficiency in generating and utilising 1O2 for pollutant degradation. Test results show that this novel technology can completely degrade bisphenol A, a common and harmful pollutant, in just 86 milliseconds (one thousandth of a second), outperforming many existing cleanup methods.

More sustainable and efficient wastewater treatment

Professor Zhao said: “This research marks a significant advancement in the field of water treatment and represents a promising strategy for addressing environmental pollution. By effectively integrating the processes of O2 activation and pollutant degradation within a single membrane, this technology offers a more sustainable and efficient approach to treating contaminated water.

“The ability to generate reactive oxygen species without external energy inputs makes this membrane particularly suitable for emergency pollution remediation and everyday water treatment applications,” he added.

Application of the NGCF-OV membrane is not limited to the degradation of a specific pollutant like bisphenol A. Instead, its catalytic properties can be harnessed for the degradation of a variety of organic pollutants in wastewater, such as antibiotics, pesticides, dyes, etc. It paves the way for more advanced practical pollution remediation technologies and contributes to the broader goal of protecting public health and preserving the environment.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/hkbu-develops-new-catalytic-membrane-that-boosts-efficiency-of-cleaning-wastewater-using-oxygen-302459978.html

SOURCE Hong Kong Baptist University

  • Largest Series A financing round in Asia’s diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific’s breakthrough diagnostic technology and growth vision.
  • Investment to accelerate R&D and commercialization of cutting-edge early disease detection technology for multiple cancers, women’s health issues, and infectious diseases.

HONG KONG, May 19, 2025 /PRNewswire/ — PHASE Scientific International Limited (“PHASE Scientific”), a pioneering biotechnology company revolutionizing early disease detection through proprietary urine-based diagnostics, today announced the successful completion of a US$34 million Series A funding round. This represents the largest Series A raise in Asia’s diagnostic technology sector since 2019, reflecting robust investor conviction in PHASE Scientific’s innovative PHASIFY™ technology and ambitious growth strategy. The funding round is led by a private equity fund managed by Value Partners Group (HKEX: 0806), one of Asia’s largest independent asset management firms, with significant backing from new healthcare-focused investors and continued support from existing global backers.

Building on its patented PHASIFY™ urine concentration technology—which captures over ten times more biomarkers than current industry gold standards—PHASE Scientific is the only player advancing a pipeline of urine-based liquid biopsy diagnostics. The company is developing a comprehensive suite of non-invasive tests for early detection of cancers, women’s health conditions, and infectious diseases. Unlike traditional invasive screening methods, PHASIFY™ enables convenient, at-home sample collection, empowering proactive health management and preventive care.

PHASE Scientific has demonstrated strong market traction with the successful launch and commercialization of over 30 innovative diagnostic products across multiple health categories, including respiratory, gastrointestinal, women’s, sexual, pediatric health, and oncology. To date, the company has distributed more than 100 million tests in over 30 countries and conducted over 8 million laboratory tests worldwide. Building on this commercial success, PHASE Scientific has developed the world’s first urine-based HPV test—a major breakthrough that has achieved significant clinical validation and global recognition. In a recent clinical study with Peking University Shenzhen Hospital, the test demonstrated 93.4% sensitivity in detecting CIN2+ lesions—including cervical precancer and cancer—and over 97% concordance with gold-standard physician-collected testing (Roche’s Cobas 4800) for HPV types 16 and 18. The innovation earned the Thomas V. Sedlacek, MD, Prize for Best Clinical Research Abstract at the 2025 American Society for Colposcopy and Cervical Pathology (ASCCP) Annual Scientific Meeting and was featured at the Chinese Society for Colposcopy and Cervical Pathology (CSCCP) Conference, reflecting growing international interest and recognition. These results underscore PHASiFY™’s potential to make cervical cancer screening more accessible, comfortable, and user-friendly.

“The successful close of this landmark Series A financing validates the transformative potential of our technology and the growing global demand for accessible, accurate early disease detection,” said Dr. Ricky Chiu, Founder, Chairman and CEO of PHASE Scientific. “With this capital, we will accelerate R&D and commercialization efforts to bring a comprehensive suite of next-generation urine-based diagnostics to market. Our mission is to empower millions worldwide with non-invasive, user-friendly testing that can save lives through earlier intervention.”

“We are delighted to become a partner of PHASE Scientific as it rapidly grows and addresses critical unmet needs in early disease detection. Its innovative technology represents a paradigm shift, offering an unparalleled combination of clinical precision and patient-centric solutions that accelerates the development of early disease detection. This aligns with our strategy to back category-defining leader with strong management, clear strategic differentiation, and best-in-class healthcare technologies that deliver both societal impact and scalable commercial potential,” said Dr. Chuen Yan Leung, Partner (Healthcare Investments) of Value Partners Group.

Founded in 2015, the company is headquartered in Hong Kong SAR with cross-border setup in Southern California, U.S.A. and China’s Greater Bay Area, which allows it to leverage the strengths of each region for research, development, and commercialization, positioning PHASE Scientific at the nexus for healthcare innovation on a global stage.

Note to Editor: The global liquid biopsy market, fueled by the demand for non-invasive cancer diagnostics, is forecasted to reach around US$22.69 billion by 2034 at a CAGR of 13.91% from US$7.05 billion in 2025, according to Precedence Research.

About PHASE Scientific

PHASE Scientific is a fast-growing biotechnology company with a mission to inspire a new state of health through innovative diagnostics and healthcare solutions. With operations in the U.S., mainland China, and Hong Kong SAR, PHASE delivers novel diagnostic tools and services for cancer and infectious diseases using proprietary technologies, empowering better disease detection, diagnosis, and management.

Since its founding, the company has been supported by Gates Foundation, US governmental agencies National Science Foundation and National Institute of Health, Ministry of Science and Technology of China, Hong Kong Innovation, Technology and Industry Bureau and Hong Kong Science and Technology Parks. For more information, please visit phasescientific.com

About PHASIFY™

PHASIFY™ is the world’s first urine concentration technology designed for molecular diagnostics, setting a new industry benchmark by capturing approximately 10 times more target analytes from urine specimens compared to the current gold standard. This advanced mechanism enables the concentration and purification of unlimited volumes of urine, dramatically increasing the sensitivity and accuracy of disease detection.

This proprietary innovation uniquely positions PHASE Scientific as the only player in the urine-based liquid biopsy diagnostics field, with proven clinical performance for multi-cancer detection. With a non-invasive and painless approach, PHASIFY™ empowers convenient sample collection, unlocking new possibilities for early, accessible, and comprehensive disease screening and diagnosis.

About Value Partners Group Limited

Value Partners, one of Asia’s leading independent asset management firms, seeks to offer world-class investment services and products. Since its establishment in 1993, the Company has been a dedicated, specialist value investor in Greater China and Asia. In November 2007, Value Partners Group became the first asset management firm to be listed on the Main Board of the Hong Kong Stock Exchange (Stock code: 806 HK). In addition to its Hong Kong headquarters, the firm operates in Shanghai, Shenzhen, Singapore and London. Value Partners’ investment strategies cover equities, fixed income, multi-asset, alternatives, real estate and quantitative investment solutions, for institutional and individual clients in Asia Pacific, Europe and the United States. For more information, please visit www.valuepartners-group.com.

Media Contact

PHASE Scientific
pr@phasesci.com

FGS Global
PhaseSci@fgsglobal.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/phase-scientific-raises-us34-million-series-a-round-to-advance-urine-based-diagnostic-technology-for-early-disease-detection-302459075.html

SOURCE PHASE Scientific

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.